Ubs Asset Management Americas Inc Halozyme Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 496,344 shares of HALO stock, worth $33.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
496,344
Previous 416,262
19.24%
Holding current value
$33.2 Million
Previous $26.6 Million
2.79%
% of portfolio
0.01%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding HALO
# of Institutions
605Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.18 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$820 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$397 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$232 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$228 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.33B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...